 |
|
A Prescribing Cascade Involving Cholinesterase Inhibitors and Anticholinergic Drugs
Sudeep S. Gill, MD, MSc, FRCPC;
Muhammad Mamdani, PharmD, MA, MPH;
Gary Naglie, MD, FRCPC;
David L. Streiner, PhD;
Susan E. Bronskill, PhD;
Alexander Kopp, BSc;
Kenneth I. Shulman, MD, SM, FRCPC;
Philip E. Lee, MD, FRCPC;
Paula A. Rochon, MD, MPH, FRCPC
Arch Intern Med. 2005;165:808-813.
Background The prescribing cascade model involves the misinterpretation of an adverse reaction to 1 drug and the subsequent, potentially inappropriate prescription of a second drug. We present a new example of the prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs used to manage urinary incontinence.
Methods A population-based retrospective cohort study was carried out in Ontario, Canada. Participants included 44 884 older adults with dementia (20 491 were dispensed a cholinesterase inhibitor and 24 393 were not), enrolled between June 1, 1999, and March 31, 2002. Subjects were observed until they received an anticholinergic drug, stopped the cholinesterase inhibitor treatment, died, or the study period ended (March 31, 2003). The main outcome measure was receipt of an anticholinergic drug to manage urinary incontinence.
Results After adjusting for potential confounding factors, we observed that older adults with dementia who were dispensed cholinesterase inhibitors had an increased risk of subsequently receiving an anticholinergic drug (4.5% vs 3.1%; P<.001; adjusted hazard ratio, 1.55; 95% confidence interval, 1.39-1.72), relative to those not receiving cholinesterase inhibitors. This finding was consistent in a series of subgroup analyses.
Conclusions Use of cholinesterase inhibitors is associated with an increased risk of receiving an anticholinergic drug to manage urinary incontinence. The use of an anticholinergic drug in this setting may represent a clinically important prescribing cascade. Clinicians should consider the possible contributing role of cholinesterase inhibitors in new-onset or worsening urinary incontinence and the potential risk of coprescribing cholinesterase inhibitors and anticholinergic drugs to patients with dementia.
Author Affiliations: Institute for Clinical Evaluative Sciences (Drs Gill, Mamdani, Bronskill, and Shulman and Mr Kopp); University Health Network, Toronto General Research Institute (Dr Naglie); and Kunin-Lunenfeld Applied Research Unit, Toronto (Drs Streiner, Lee, and Rochon), Toronto, Ontario.
RELATED ARTICLE
Guided Prescription of Psychotropic Medications for Geriatric Inpatients
Josh F. Peterson, Gilad J. Kuperman, Caroline Shek, Minalkumar Patel, Jerry Avorn, and David W. Bates
Arch Intern Med. 2005;165(7):802-807.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Dementia and Comorbidities: An Overview of Diagnosis and Management
Swanson and Carnahan
Journal of Pharmacy Practice 2007;20:296-317.
ABSTRACT
The staging and assessment of moderate to severe Alzheimer disease
Feldman and Woodward
Neurology 2005;65:S10-S17.
ABSTRACT
| FULL TEXT
|
